Track Rafael Holdings, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Rafael Holdings, Inc. RFL · Stock Open Rafael Holdings, Inc. in new tab

1.07 USD
EPS
-0.58
P/B
0.87
ROE
-32.82
Beta
0.72
Loading chart...
Key Metrics
Earnings dateDec. 10, 2026
EPS-0.58
Book Value1.27
Price to Book0.87
Debt/Equity0.85
% Insiders38.078%
Growth
Revenue Growth-0.30%

DCF valuation

Model fair value for Rafael Holdings, Inc. (RFL)
Result
Sign in to run the valuation for RFL.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Rafael Holdings, Inc. Logo Rafael Holdings, Inc. Analysis (RFL)

United States Health Care Official Website Stock

Is Rafael Holdings, Inc. a good investment? Rafael Holdings, Inc. (RFL) is currently trading at 1.07 USD.

Earnings Schedule: Rafael Holdings, Inc. is expected to release its next earnings report on Dec. 10, 2026.

Investor FAQ

Does Rafael Holdings, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Rafael Holdings, Inc.?

Rafael Holdings, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Dec. 10, 2026. The company currently has a trailing EPS of -0.58.

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C (NPC), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate. The company is also involved in developing Promitil, a pegylated liposomal mitomycin-C lipidic prodrug which is designed molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form. In addition, it develops surgical and procedural devices, including orthopedic arthroscopy instrument for carpal and cubital tunnel syndrome. Further, the company provides technological solutions specifically engineered for increased bioavailability of cannabinoids. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Exchange Ticker
NYQ (United States) RFL
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2009
0.04 USD
Dec. 31, 2009 0.0200
June 30, 2009 0.0200
Stock Splits
Split Date Split Ratio to 1
May 9, 2025 1.01
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion